Insider Transactions in Q1 2022 at Sangamo Therapeutics, Inc (SGMO)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 25
2022
|
Prathyusha Duraibabu SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
345
-0.39%
|
$1,725
$5.75 P/Share
|
|
Feb 25
2022
|
Robert Carey |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+25.93%
|
-
|
|
Feb 25
2022
|
Kenneth J. Hillan |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+25.93%
|
-
|
|
Feb 25
2022
|
John Markels |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+32.72%
|
-
|
|
Feb 25
2022
|
James R Meyers |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+25.93%
|
-
|
|
Feb 25
2022
|
H Stewart Parker |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+22.24%
|
-
|
|
Feb 25
2022
|
Saira Ramasastry Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+25.93%
|
-
|
|
Feb 25
2022
|
Karen L. Smith |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+24.65%
|
-
|
|
Feb 25
2022
|
Joseph S Zakrzewski Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+17.08%
|
-
|
|
Feb 25
2022
|
Sandy Macrae PRESIDENT, CEO AND DIRECTOR |
BUY
Grant, award, or other acquisition
|
Direct |
224,000
+30.06%
|
-
|
|
Feb 25
2022
|
Sandy Macrae PRESIDENT, CEO AND DIRECTOR |
SELL
Payment of exercise price or tax liability
|
Direct |
49,890
-14.37%
|
$249,450
$5.9 P/Share
|
|
Feb 25
2022
|
David Mark Mc Clung EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
59,400
+24.31%
|
-
|
|
Feb 25
2022
|
David Mark Mc Clung EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,610
-3.54%
|
$23,050
$5.9 P/Share
|
|
Feb 25
2022
|
Prathyusha Duraibabu SVP, CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
41,000
+31.84%
|
-
|
|
Feb 25
2022
|
Prathyusha Duraibabu SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,474
-6.91%
|
$17,370
$5.9 P/Share
|
|
Feb 25
2022
|
Jason D. Fontenot SVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,100
+30.25%
|
-
|
|
Feb 25
2022
|
Jason D. Fontenot SVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,248
-9.59%
|
$31,240
$5.9 P/Share
|
|
Feb 25
2022
|
Rolf Andrew Ramelmeier EVP, Technical Operations |
BUY
Grant, award, or other acquisition
|
Direct |
54,000
+27.49%
|
-
|
|
Feb 25
2022
|
Rolf Andrew Ramelmeier EVP, Technical Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
12,388
-12.29%
|
$61,940
$5.9 P/Share
|
|
Feb 25
2022
|
Robert J. Schott SVP, Head of Development |
BUY
Grant, award, or other acquisition
|
Direct |
41,000
+35.18%
|
-
|
|
Feb 25
2022
|
Scott B. Willoughby SVP, GEN. COUNSEL & SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
41,000
+30.19%
|
-
|
|
Feb 25
2022
|
Scott B. Willoughby SVP, GEN. COUNSEL & SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
1,566
-2.83%
|
$7,830
$5.9 P/Share
|
|
Feb 12
2022
|
Robert J. Schott SVP, Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
5,463
-13.66%
|
$27,315
$5.76 P/Share
|